Search Results
Your search for ,OUr matches 10645 pages
Showing 2501 - 2550Managing Long-Term Toxicity From Pelvic Radiation Therapy
Advances over the past 3 decades in improvements in cancer prevention and screening strategies and more effective diagnostics and therapies in cancer care have led to unprecedented declines in death rates from all cancers, including prostate, gynecologic, and colorectal/anal cancers. The fastest...
The Road to a Career in Breast Oncology Took Several Twists and Turns for Sara A. Hurvitz, MD, FACP
Breast cancer specialist Sara A. Hurvitz, MD, FACP, grew up in the East Bay area of Northern California, the youngest of five children. “My mother was a traditional stay-at-home mom, and my father was a probation officer. I come from a long line of artists; my great-grandfather on my mother’s side...
Time for a Radical Change in the Treatment of Endometrial Cancer: KEYNOTE-775 and Beyond
I had the privilege of sitting in a meeting on the treatment of endometrial cancer as a junior investigator in January 2015 where a representative from the U.S. Food and Drug Administration was present. The topic of the meeting was on how to design the next endometrial cancer trials. I remember...
Clinical Trials Underway for T-DXd in Breast Cancer
The current standard of care for the neoadjuvant treatment of HER2-positive early-stage breast cancer consists of trastuzumab plus pertuzumab and polychemotherapy. But some patients, particularly those with locally advanced or inflammatory disease, still relapse and die. Furthermore, multiagent...
ABC Sixth International Consensus Conference Updates Guidelines for Advanced Breast Cancer
New recommendations for treating advanced breast cancer, coming from a panel of experts at the Advanced Breast Cancer (ABC) Sixth International Consensus Conference (ABC6), were recently published.1 The report highlights advances that have resulted in robust improvements in overall survival for...
Margaret von Mehren, MD, Appointed New Vice Chair of Department of Hematology/Oncology at Fox Chase
Margaret von Mehren, MD, Chief of the Division of Sarcoma Medical Oncology at Fox Chase Cancer Center, was recently appointed the new Vice Chair of the Department of Hematology/Oncology. “It is an honor to serve the Department of Hematology and Oncology, which I have been a member of since 1993,...
Iberia Romina Sosa, MD, PhD, Appointed New Chief of Division of Hematology at Fox Chase
Iberia Romina Sosa, MD, PhD, Associate Professor at Fox Chase Cancer Center, was recently appointed as the new Chief of the Division of Hematology in the Department of Hematology/Oncology. “I feel truly privileged to have been offered this role and to have the opportunity to work with such a...
Expert Point of View: Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine, said the “fascinating” findings of the study reported by Bouzid et al make it worthy of an ASH Plenary Session...
Memorial Sloan Kettering President and Chief Executive Officer, Craig B. Thompson, MD, to Step Down
Craig B. Thompson, MD, announced his intention to step down as President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK) and has asked the Boards of Trustees and Governing Trustees to begin a search for his successor. Dr. Thompson will continue in his role until the...
Combinations Advance the Power of Pembrolizumab in Hodgkin Lymphoma
Pembrolizumab monotherapy is an established treatment strategy for relapsed or refractory classical Hodgkin lymphoma. In combination with chemotherapy, the checkpoint inhibitor is also showing value in the front-line setting and further boosting outcomes in the relapsed setting, according to...
Laura Bukavina, MD, MPH, Wins ASCO Genitourinary Conquer Cancer Merit Award for Microbiome Research in Bladder Cancer
Laura Bukavina, MD, MPH, a Urologic oncology fellow at Fox Chase Cancer Center, has been awarded the ASCO Genitourinary Conquer Cancer Merit Award. She presented the winning abstract, which characterizes the gut microbiome of patients with bladder cancer, at the 2022 ASCO Genitourinary (GU) Cancers ...
Grieving the Loss of Sexual Intimacy as a Result of Cancer and Its Treatment
About 5 years ago, I began experiencing some digestive issues that I initially blamed on the stress from coping with my mother’s diagnosis of Alzheimer’s disease. But after 2 weeks of unrelenting symptoms, including abdominal pain, a change in my bowel habits, and rectal bleeding, I saw my primary...
Cancer in the Arab World: Addressing Challenges to Improve Outcomes
I returned home to the United Arab Emirates in 2017, following my oncology fellowship training and work experience in the United States. I immediately realized that I am now dealing with a considerably different cancer patient population in terms of age of onset, stage at presentation, awareness...
From a Low-Income Family in Puerto Rico, to a Leadership Role in Oncology for Gerardo Colón-Otero, MD
In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Gerardo Colón-Otero, MD, Professor of Medicine at Mayo Clinic College of Medicine, Past Chair of the Division of Hematology/Oncology at the Mayo Clinic in Florida, and Vice Dean at Mayo Clinic Alix School of...
Leukemia Committee of National Cooperative Clinical Trials Group Names New Co-Chairs
A network sponsored by the National Cancer Institute, the Leukemia Committee of the Alliance for Clinical Trials in Oncology promotes collaboration between approximately 10,000 cancer specialists across the United States and Canada. The Committee recently announced the results of an international...
Emerging Issues Regarding Artificial Intelligence in Cancer Research and Clinical Practice
Artificial intelligence (AI) has captured society’s imagination and generated enthusiasm for its potential to improve our quality of life, especially in the health-care arena. The availability of high-dimensionality data sets along with innovations in high-performance computing and deep-learning...
Small Study Reports Neoadjuvant PD-1 Blockade Yields 100% Clinical Complete Response Rate in Locally Advanced Mismatch Repair–Deficient Rectal Cancer
In a small study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, treatment with the anti–PD-1 agent dostarlimab-gxly alone led to a clinical complete response rate of 100%. The findings of this study from Memorial Sloan Kettering Cancer Center (MSK) were reported...
Expert Point of View: Samuel J. Klempner, MD
Samuel J. Klempner, MD, Associate Professor at Massachusetts General Hospital and Harvard Medical School, commented on the NEONIPIGA study for The ASCO Post. “This study was the first prospective data set to show what many have suspected—that neoadjuvant immune checkpoint blockade would lead to a...
Noninvasive Diagnosis of CNS Lymphoma Possible Through ctDNA
Circulating tumor DNA (ctDNA) is readily detectable in the plasma and cerebrospinal fluid of patients with central nervous system (CNS) lymphoma and is a strong prognostic biomarker for outcomes, a team of researchers from Germany and Stanford University reported at the 2021 American Society of...
Research Outlines Obstetric and Perinatal Outcomes for Female Survivors of Childhood Cancer
Survivors of childhood cancer who become pregnant in adulthood are as likely to have healthy babies as those without a history of cancer, according to a new study published by Zgardau et al in the Journal of the National Cancer Institute. Their children also don’t have higher risks of birth defects ...
SBRT in Combination With Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Pancreatic Cancer
In a Chinese single-institution phase II trial reported in The Lancet Oncology, Zhu et al found that stereotactic body radiotherapy (SBRT) followed by pembrolizumab plus trametinib improved overall survival vs SBRT followed by gemcitabine in patients with postresection, KRAS-mutant, PD-L1–positive...
President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All Americans
Much progress has been made in the past 50 years since the signing of the National Cancer Act of 1971, which included the establishment of the President’s Cancer Panel. Nevertheless, there remain significant opportunities to make improvements across the cancer spectrum, perhaps none more pressing...
Humanitarian Paul Farmer, MD, PhD, Dies at 62
"One of the great advocates for the poorest and sickest of our planet.” —Nobel Peace Prize laureate Archbishop Desmond Tutu “Our mission is to provide a preferential option for the poor in health care. By establishing long-term relationships with sister organizations ...
Societies Team Up to Provide Support for Ukrainian Patients With Cancer
According to the United Nations (UN), more than 1.7 million Ukrainians have already fled to Central Europe due to the Russian invasion, which the UN High Commissioner for Refugees has called the fastest-growing refugee crisis in Europe since World War II. Many of those fleeing Ukraine and those...
Disadvantaged Patients Less Likely to Receive Advanced Radiotherapy Techniques for Head and Neck Cancer
Advanced radiotherapy techniques can reduce the risk of severe and debilitating toxicity associated with radiation, but not all patients have equal access to these modalities, according to data presented by Neal S. McCall, MD, at the 2022 Multidisciplinary Head and Neck Cancers Symposium (Abstract...
Study Defines Stem Cell Groups That May Drive Development of Myelodysplastic Syndromes
Researchers have discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) may be caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells. Their findings, which could have significant benefits for patients with...
Midtreatment Imaging De-escalates Therapy for Half of Patients With Oropharyngeal Cancer
Positron-emission tomography (PET) scans obtained before and midway through treatment can be used to de-escalate therapy for oropharyngeal cancer, potentially leading to fewer short-term side effects, according to data presented by Allen et al at the 2022 Multidisciplinary Head and Neck Cancers...
Pain and Quality of Life in the PROfound Trial: Olaparib vs Next-Generation Hormonal Agent in Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
In an analysis from the phase III PROfound trial reported in The Lancet Oncology, Thiery-Vuillemin et al found that olaparib was associated with better pain outcomes and preservation of health-related quality of life (QOL) vs enzalutamide or abiraterone plus prednisone in a cohort of men with...
Expert Point of View: Amy Tiersten, MD, and Carlos L. Arteaga, MD
Amy Tiersten, MD, Professor of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, and Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology at The University of Texas Southwestern Medical Center, Dallas,...
PADA-1 Trial: With Early Identification of ESR1 Mutation, Switch to Fulvestrant in Metastatic Breast Cancer
Switching from an aromatase inhibitor to fulvestrant upon early identification of the ESR1 mutation in plasma—before disease progression—doubled progression-free survival in the phase III PADA-1 trial, presented at the 2021 San Antonio Breast Cancer Symposium.1 “PADA-1 is the first trial to...
Expert Point of View: David Cescon, MD, PhD
David Cescon, MD, PhD, Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Canada, was the invited discussant of the two MONALEESA analyses.1,2 He noted that the most recent overall survival analysis, presented at the European Society for Medical Oncology (ESMO) Congress 2021,...
RxPONDER Update Explores Benefit of Chemotherapy in Subgroups
Updated results of the SWOG S1007 RxPONDER trial confirmed the key takeaway from the previous analysis: adjuvant chemotherapy benefits premenopausal women but not postmenopausal women with hormone receptor–positive, HER2-negative disease, one to three positive lymph nodes, and a 21-gene Oncotype DX ...
KEYNOTE-522: Sensitivity Analyses Confirm Value of Neoadjuvant Pembrolizumab in Triple-Negative Breast Cancer
Updated results from the pivotal KEYNOTE-522 trial have confirmed the benefit of neoadjuvant therapy with pembrolizumab plus chemotherapy in patients with early triple-negative breast cancer.1 The results were presented at the 2021 San Antonio Breast Cancer Symposium by Peter Schmid, MD, PhD,...
Clinical Trials Underway for T-DXd in Breast Cancer
The current standard of care for the neoadjuvant treatment of HER2-positive early-stage breast cancer consists of trastuzumab plus pertuzumab and polychemotherapy. But some patients, particularly those with locally advanced or inflammatory disease, still relapse and die. Furthermore, multiagent...
Highlights From the 2021 San Antonio Breast Cancer Symposium
In its first return to a hybrid model since the COVID-19 pandemic began, the 2021 San Antonio Breast Cancer Symposium (SABCS) brought together researchers, clinicians, industry experts, patients, and advocates from across the globe to present and grapple with new data and important topics in breast ...
Study Identifies New Mutation That May Define Novel Pediatric AML Subtype
A new mutation was identified in 9% of relapsed cases of pediatric acute myeloid leukemia (AML) that may define a new subtype of the disease, according to a study published by Umeda et al in Blood Cancer Discovery. The mutation is a tandem duplication (a series of adjacent repeats of a DNA...
T-Cell Responses May Help Predict Protection Against SARS–CoV-2 Infection in Individuals With and Without Cancer
T-cell responses directed against the receptor-binding domain of the SARS–CoV-2 spike protein were associated with protection from SARS–CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers, according to results from a...
Isatuximab-Containing Induction Therapy for Multiple Myeloma Increases Measurable Residual Disease Negativity
For the first-line treatment of newly diagnosed multiple myeloma, the percentage of patients achieving measurable residual disease (MRD, previously called minimal residual disease) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to a standard...
Expert Point of View: Philip L. McCarthy, MD
The ASCO Post invited myeloma expert Philip L. McCarthy, MD, Director of the Transplant and Cellular Therapy Program at Roswell Park Comprehensive Cancer Center, Buffalo, New York, to comment on the trials evaluating early detection of myeloma at the 2021 American Society of Hematology (ASH) Annual ...
Studies Evaluate Screening for Early Multiple Myeloma
Precursors to multiple myeloma were identified by population screening in two studies reported at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. The prevalence of monoclonal gammopathies was determined in the PROMISE trial using cutting-edge technology in a high-risk ...
Mosunetuzumab Meets Primary Endpoint of Phase II Trial in Relapsed or Refractory Follicular Lymphoma
The bispecific antibody mosunetuzumab achieved deep and durable remissions as monotherapy in patients with relapsed or refractory follicular lymphoma, according to the results of a pivotal phase II trial presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In ...
Patricia L. Turner, MD, MBA, FACS, Takes Helm of American College of Surgeons
Patricia L. Turner, MD, MBA, FACS, formally assumed the role of Executive Director of the American College of Surgeons (ACS) on January 1, 2022, ushering in a new era of leadership for the educational and professional society for surgeons. Dr. Turner succeeds David B. Hoyt, MD, FACS, MAMSE, who led ...
Why Some Patients With Cancer Are Reluctant to Receive COVID-19 Vaccination: Survey Shows Need to Improve Patient-Physician Communication
“My doctor has not told me to get the vaccine.” That was the number one reason patients with cancer gave in a survey at an outpatient infusion therapy clinic for not having received at least one dose of the COVID-19 vaccine. Rivalling that reason were concerns about safety and fear of vaccine side...
Reflecting on the Past 50 Years of Cancer Progress and Looking Ahead to the Next 50 Years of Advances
In December 2021, Nobel laureates, cancer center directors, physicians, scientists, politicians, public health officials, and patient advocates gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to celebrate the 50th anniversary of the signing of the National...
M. Eileen Dolan, PhD, Named Deputy Director of the University of Chicago Medicine Comprehensive Cancer Center
The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) has appointed renowned cancer researcher M. Eileen Dolan, PhD, as its Deputy Director. Dr. Dolan, Professor of Medicine at the University of Chicago, has spent the past 8 years working as UCCCC’s Associate Director for Cancer...
New Guideline Offers Most Comprehensive Summary to Date of Therapies for Brain Metastases
In an effort to synthesize findings from multiple guidelines on various management approaches for brain metastases, ASCO, the Society for Neuro-Oncology (SNO), and the American Society for Radiation Oncology (ASTRO) spearheaded the development of a novel publication to inform and update physician...
Moonshot Expansion Offers Opportunity to Increase Equity in Cancer, Recover Progress on Screening
On February 2, 2022, Howard A. “Skip” Burris III, MD, FACP, FASCO, Board Chair of the Association for Clinical Oncology, issued the following statement: “The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy ...
ASCO and American Cancer Society Announce Collaboration to Empower People With Cancer Information They Can Trust
ASCO and the American Cancer Society (ACS) initiated a collaboration to ensure that people can easily find the trusted, expert-approved cancer content they need when turning to either organization for information. As an initial step, the organizations are cross-sharing select cancer prevention,...
Single-Cell Spatial Connectivity Analysis Offers ‘Unprecedented’ Information in Breast Cancer
A next-generation technology that focuses on protein expression at the single-cell level has yielded a wealth of information about “spatial connectivity” between cancer cells and their microenvironment. It also provided information on the benefit of adding the immune checkpoint inhibitor...
In Case You Missed It: Brief Highlights From the 2021 ASH Annual Meeting & Exposition
COVID has upended our world, and medical conferences have had to adapt to ever-shifting sands depending on the behavior of the variants of the virus that emerge. The 2021 American Society of Hematology (ASH) Annual Meeting & Exposition was no exception, offering a hybrid meeting for in-person...
